In a retrospective analysis of advanced CCA patients receiving lenvatinib plus PD-1/PD-L1 inhibitors and combined with gemcitabine and oxaliplatin (Gemox) chemotherapy, Zhu et al. This evidence concerns the gene PDCD1 and cholangiocarcinoma.